Activation of PI3-K-AKT and ERK pathways is a complication of mTOR inhibitor therapy.
Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple …

The mammalian target of rapamycin (mTOR) is centrally located, linking proximal oncogenic
cascades to critical downstream pathways that drive tumor growth. mTOR regulates such …

Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have
shown preclinical potential as therapy for multiple myeloma. By inhibiting expression of cell …

Mammalian target of rapamycin (mTOR) is a downstream serine/threonine kinase of the
PI3K/Akt pathway that integrates signals from the tumor microenvironment to regulate …

Previous studies have demonstrated the in vitro and in vivo activity of CC-5013 (Revlimid),
an immunomodulatory analog (IMiD) of thalidomide, in multiple myeloma (MM). In the …

The mammalian target of rapamycin (mTOR) is extensively involved in multiple myeloma
(MM) pathophysiology. In the present study, we reported a novel small molecule SC06 that …

Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma,
resistance to these drugs may arise via feedback activation loops. This concern is especially …

The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and
plays a critical role in modulating proliferation, growth, survival, invasion and …

The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma
(MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors …

We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-
779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in …